Euconvisio Life Sciences-B (01477): The second phase III clinical trial of OT-301 has reached the primary endpoint.

The latest news from the Cheung Kong Financial APP shows that Ocumension Therapeutics Ltd-B (01477) announced that one of the group's main candidate drugs, OT-301 (NCX 470) (a nitric oxide (NO) donor-type prostaglandin analogue co-developed by Nicox S.A. (Nicox) and the group) has achieved non-inferiority to latanoprost in its phase III clinical trial (Denali trial), meeting the efficacy requirements for new drug approval in China. OT-301 has shown good safety and patient tolerance in the Denali trial. In addition, in the pre-specified secondary efficacy analysis, OT-301 demonstrated statistically significant advantages in reducing baseline intraocular pressure compared to latanoprost, with p-values less than 0.05 at three out of six time points.